Moberg Pharma AB · OMXSTO:MOB
Moberg Pharma AB — Bio Europe Frankfurt 2014
21 slides from Moberg Pharma AB's conference presentation, Nov 4, 2014
Slide 1: Moberg Pharma AB
Moberg Pharma AB Combining Commercial and Innovation Excellence to provide unique products in underserved markets Corporate Presentation – Bio Europe Frankfurt November 4, 2014 Peter Wolpert, CEO & Founder 0
Slide 2: Disclaimer
Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forward- looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma’s results could
Slide 3: 2014 TV commercial in the Nordics
2014 TV commercial in the Nordics 2 2
Slide 4: Moberg Pharma
Moberg Pharma COMBINING COMMERCIAL AND INNOVATION EXCELLENCE Vision Strategic plan Build a mid-size Pharma/Consumer Growth strategy Health company with direct Sales in: - Organic growth - U.S. and select countries - Innovation engine incl M&A - OTC and select specialty areas Build value throug
Slide 5: Moberg Pharma
Moberg Pharma COMBINING COMMERCIAL AND INNOVATION EXCELLENCE Net Sales grew to 178 MSEK (TTM, Q214) - U.S. OTC Sales operations - Products sold in 40+ countries - 30 employees in Sthlm and NJ Focus in OTC/Dermatology/Topicals - Leading U.S. OTC SKU in Nail Fungus - Superior PII data for MOB015
Slide 6: Rapid growth in sales and EBITDA
Rapid growth in sales and EBITDA (MSEK) +58% in Direct sales 157 112 106 Milestones 56 Product Sales Net Sales 2011 2012 2013 2014 H1 13 14 13 EBITDA EBITDA -8 -8 -13 EBITDA excluding -16 milestone payments -29 5 5
Slide 7: 17 consecutive quarters of sales growth
17 consecutive quarters of sales growth Product Sales, TTM, MSEK 2014 Highlights Kerasal Nail no 1 200 SKU in U.S., 175 23% mkt share Leading nail fungus 150 SKU in many other countries 125 Preparing launches in China and SE Asia 100 Superior phase II 75 data for MOB015 21% Commercial 50 E
Slide 8: Majority of revenue from direct OTC sales
Majority of revenue from direct OTC sales – Strong contribution to earnings from both channels Distribution of revenue, Jan – June 2014 JointFlex Other RoW Sales via 12% 12% 4% distributors Europe 32% Kerasal 22% 16% Nalox/ Direct OTC Kerasal Nail Americas Sales 68% 60% 74% Channels Products Geograp
Slide 9: Commercial Operations & Innovation Engine
Commercial Operations & Innovation Engine
Slide 10: Building brand equity in the U.S. on a cost effective platform
Building brand equity in the U.S. on a cost effective platform CMOs Sales Force Retailers/Wholesalers Sales and marketing/Brand Management Logistics Emerson Healthcare 9 9
Slide 11: Outperforming the market through combining Brand and IP equity
Outperforming the market through combining Brand and IP equity Organic growth 2014 H1 (Value), percent Strategic brands • Kerasal® - Foot care 31% • Domeboro® - Derma/Skin irritation) Mature brands • Jointflex (intern. analgesic®) • Vanquish (ext. analgesic®) 5% • Fergon (Iron supplement®) Moberg U.
Slide 12: Distributor Sales well positioned for further growth
Distributor Sales well positioned for further growth Nalox™/Kerasal Nail® Sales in >40 markets 10% growth in Europe – implementation of new stronger claims just started. Potential for further growth Strong sales in Canada as response to launch of consumer advertising, Market leader with 25
Slide 13: Pipeline assets in phase II
Pipeline assets in phase II - Building on Topical drug delivery know how and IP portfolio Peak sales Pipeline Indication Status potential, m$ USP asset MOB-015 Onychomycosis Phase II 250-500 Topical terbinafine with fast visible improvement and superior cure rates BUPI Oral Mucositis Phase II 50-100
Slide 14: Excellent Phase II results
Excellent Phase II results FINAL RESULTS AT 15 MONTHS (60 WEEKS) 54% Study design Open label, n=25, 24 patients completed Once daily for 48w Last follow-up at 60w MYCOLOGICAL CURE Severely affected nails, majority had 29% >50% nail involvement MYCOLOGICAL CURE AND EXCELLENT CLINICAL IMPROVEMEN
Slide 15: Phase II results indicate MOB015 potential to become best in class
Phase II results indicate that MOB015 have potential to become best in class (topical drug for Onychomycosis) Mycological cure Active Product Company Form at 6 months at 12/15 Comment months Terbinafine MOB-015 Moberg Pharma Topical 40%1) 54% 25-75% affected Ciclopirox Penlac Valeant Topical - 29-36
Slide 16: Example of successful treatment with MOB-015
Example of successful treatment with MOB-015 Before After 15 15
Slide 17: Example of successful treatment with MOB-015
Example of successful treatment with MOB-015 Before After 16 16
Slide 18: Example of successful treatment with MOB-015
Example of successful treatment with MOB-015 Before After 17 17
Slide 19: Phase II results provide evidence of efficacy and safety
Phase II results provide evidence of efficacy and safety 54% mycological cure, in spite of severity of patients included Excellent clinical improvement, full photo documentation High terbinafine levels in patients: - In nail bed: 45 µg/g (median value) - In nail: 1610 µg/g (median value) Saf
Slide 20: BUPI – Long-acting lozenge with bupivacaine
BUPI – Long-acting lozenge with bupivacaine - Phase II started Oct 2014 Product & Indication Bupivacaine lozenge for oral pain relief (mouth and throat) 1st indication: Oral Mucositis in cancer patients. Large unmet need Other indications: Burning Mouth Syndrome, Sjögren’s syndrome, Upper gast
Slide 21: Focus next 12 months
Focus next 12 months COMBINING COMMERCIAL AND INNOVATION EXCELLENCE Improving EBITDA Fuel strong U.S growth - K-Nail and Neurocream launch - Line extensions and new SKUs Grow Distributor Sales - EU: Extended indication - China registration, SE Asia, Mena BD focus - US OTC products MOB-015